Visfatin is an adipocytokine that has been thought to play a role in the pathogenesis of insulin resistance. Clarifying the role of Visfatin along with its correlation to insulin resistance in Diabetes and Metabolic Syndrome (MS) patients would enhance our knowledge of this novel biomarker. It was a clinic-based cross-sectional study. Serum levels of Visfatin assessed randomly in 118 patients having diabetes, Pre- diabetes, or metabolic syndrome, attending OPD in our institute. Visfatin levels measured along with BMI (Body Mass Index), Blood Pressure (BP), Lipids, Glucose, Insulin, Hs-CRP (High Sensitivity C Reactive Peptide) levels, Homeostatic model assessment is a method for insulin resistance (HOMA-IR) indexes. One-way ANOVA and linear regression analysis were carried out using SPSS 23. Average Serum Visfatin (SV) levels were significantly different in MS (n=34, 9.50±8.22), Diabetic (n=43, 12.04±7.6) and Pre-Diabetic (n=41, 9.07±8.6) groups. SV shows a significant association with fasting blood sugar (p=0.009) and BMI (p=0.038) only in MS patients. Significant correlation not found between Visfatin and insulin resistance (p=0.173) in either of the 3 groups. In the present study, SV levels were not correlated with insulin resistance in metabolic, diabetic, and pre-diabetic patients but SV showed a significant association with fasting blood sugar and BMI in MS patients.
